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Abstract
Insulin is involved in regulation of glucose utiliza-
tion in the body. Inability of the body to synthesize
insulin or human cells resistance to insulin leads to
a condition called Diabetes mellitus which is char-
acterized by chronic hyperglycaemia. There are two
types of diabetes; type 1 and type 2. Exogenous
supply of insulin is needed consistently for type 1
diabetes treatment and type 2 diabetes also needs
to be cured by the exogenous supply of insulin in
advance stages of the disease. These sources have
been proved very useful to meet the needs of the
patients. However, these insulin types are expen-
sive for the large population of patients in the de-
veloping countries. Furthermore, the incidence of
diabetes is advancing at an alarming rate. Hence
production systems with even higher capabilities
of production are desired. Therefore, currently
plants are being investigated as alternative produc-
tion systems. Based on the mode of action of insu-
lin various formulations of insulin have been devel-
oped that have different onset of action, peak ef-
fect and duration of action according to the needs
of the patients.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Insulin is an important polypeptide hormone that regu-
lates carbohydrate metabolism. Insulin is derived from
the Latin word insula meaning "island" because the
hormone is produced in the islets of langerhans. It was
discovered by Banting and Best in 1921-1922 at the
University of Toronto. It helps transport blood glucose
into the body cells where the glucose is metabolized to
produce energy. It maintains glucose concentration in
the blood. When glucose concentration in the blood is
increased, insulin lowers it by increasing glucose up-
take by muscle, liver and fat cells. Excess glucose is con-
verted to glycogen by these tissues. When glucose con-
centration is reduced in the blood, glycogen is convert-
ed back to glucose and released in the blood. It is in-
volved in regulating amino acid uptake by increasing
DNA replication and protein synthesis. Insulin facili-
tates fatty acid synthesis through the uptake of lipid
from blood by fat cells. It also decreases proteinolysis,
lipolysis and gluconeogenesis.
Insulin is synthesized by β-cells of the pancreas in the
form of a single chain of three peptides B, C and A in
the order: B chain-C peptide-A chain.1,2 This proinsu-
lin is converted to mature insulin after the removal of
the central C-peptide by the action of proteolytic en-
zymes known as prohormone convertases PCl/PC3
and PC2.3 The mature insulin consists of B-chain (30
amino acids) and A- chain (21 amino acids) linked by
two inter-chain and one intra-chain disulphide bridge.
Its structure has been highly conserved among verte-
brates.4-7
When the body is unable to produce insulin or the
body develops resistance against insulin, a metabolic
disorder called diabetes mellitus arises which leads to
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abnormal carbohydrate metabolism. Diabetes mellitus
is treated by the exogenous supply of insulin. For this
purpose, various types of insulin have been developed
with different action times according to the needs of
patients. In this review, insulin sources and types were
summarized in terms of its action mode.
Treatment of diabetes mellitus
The condition refers to a metabolic disorder character-
ized by chronic hyperglycaemia in which the patient ex-
periences disturbances in metabolism of carbohydrate,
fat and protein as a result of deficiency in insulin secre-
tion, insulin action or both.8 Diabetes is the fifth-lead-
ing causes of mortality in most developed countries
and there are thoughts to be about 246 million people
suffering from diabetes.9 It has been estimated that by
2025 there will be nearly 380 million people suffering
from diabetes if not controlled.9
There are two types of diabetes mellitus i.e. type 1 and
type 2 diabetes mellitus. Type 1 diabetes is caused by
the destruction of β-cells of pancreas that are involved
in insulin synthesis. The destruction is caused by an au-
to-immune reaction where these cells are destroyed by
the body's own defence system. As a result, very little
or no insulin is produced and hence carbohydrate, espe-
cially glucose, metabolism is disturbed leading to the
characteristic symptoms. Type 1 diabetes is also known
as insulin dependent, juvenile or immune- mediated di-
abetes. The causes of type 1 diabetes are still largely un-
known; however, both genetic and environmental fac-
tors have been implicated. Children of parents with
type 1 diabetes have an increased risk of developing the
disease. Important environmental factors include obesi-
ty, diet, physical inactivity and viral infection. Type 1
diabetes mostly affects children and young adults. Pa-
tients suffering from type 1 diabetes consistently re-
quire insulin treatment (via injection or oral adminis-
tration) for their continued survival.
Type 2 diabetes occurs as a result of insulin resistance
and relative insulin deficiency. Insulin resistance refers
to the condition where the insulin is not very effective
in reducing the blood glucose levels. Type 2 diabetes
can appear at any stage of life; however, it is mostly di-
agnosed in adults at the age of 40 or above. Symptoms
of type 2 diabetes involve frequent urination, constant
thirst, increased hunger, weight loss and tiredness. Like
type 1 diabetes both genetic and environmental factors
contribute to the development of type 2 diabetes. Ge-
netic factors leading to type 2 diabetes are not well un-
derstood, while potential environmental factors in-
clude physical inactivity, obesity, diet and aging. Pa-
tients with type 2 diabetes generally do not need to be
administered exogenous insulin; however, in extreme
cases of hyperglycemia administration of exogenous in-
sulin might be required. Treatment generally involves
controlling blood glucose, blood pressure, lipids, chang-
ing lifestyle through exercise and medication.
Treatment of diabetes involves regular monitoring of
glucose levels in the blood so as to provide insulin
when required to prevent hyperglycaemia. Necessary
changes in lifestyle and diet are also required to keep di-
abetes in control. Insulin is primarily given in the form
of injections; however, recent advances in drug delivery
have included pulmonary, oral and nasal administra-
tion routes which have been developed to overcome
the inconveniences associated with regular insulin injec-
tions.10,11
INSULIN SOURCES: PLANTS AS
ALTERNATIVE FORMASS SCALE
PRODUCTION
Since the 1920s, insulin has been used for treatment of
diabetes. The initial sources of insulin were from bo-
vine, porcine, and equine. Methods to convert porcine
insulin into the human insulin equivalent were devel-
oped in the 1970s and early 1980s.12,13 With the devel-
opment of genetic engineering and modern biotechnol-
ogy, efforts were shifted towards the production of insu-
lin through recombinant DNA technology. Human in-
sulin was one of the first pharmaceutical proteins that
were manufactured through recombinant DNA tech-
nology in the late 1970s, which has been marketed
since 1982.
Since 1980s, recombinant insulin from bacteria14 and
yeast.15 has been the main source of commercial insu-
lin. These systems have been helping to meet the de-
mand of this important pharmaceutical since this time.
However, the incidence of diabetes is increasing and
this demand for insulin cannot be provided by these
sources in the near future due to the scale and costs in-
volved. It has been estimated that the demand for insu-
lin will double in the next 10 years.16 Developing coun-
tries are facing further challenges as patients in these
countries are not able to afford the cost of this expen-
sive drug. Furthermore, alternate delivery systems such
as oral, inhalable and buccal forms which aim to pro-
vide relief to patients from the painful insulin injec-
tions require a higher amount of insulin to be effective
as a treatment as these methods are not very efficient.16
In view of the increasing demand for insulin, currently
plants are being investigated as factories for the produc-
tion of insulin which have the potential for a high
yielding and cost effective method of production for
this important pharmaceutical.17-19 In an attempt to
achieve this goal, Arakawa et al 17 produced a cholera
toxin B subunit-insulin fusion protein in transgenic po-
tato tubers as an autoantigen against insulin-dependent
diabetes mellitus. The fusion protein accumulated to
0.1% of total soluble protein. The transgenic tobacco
tuber tissues were fed to diabetic mice which helped in
the reduction of insulitis and delayed the onset of dia-
betes. Nykiforuk et al 18 expressed the desB30 form of
human insulin (lacking threonine at position B30) as
an oleosin-insulin fusion protein in Arabidopsis thali-
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ana. The fusion protein could be subsequently purified
by the oleosin fusion technology to reduce the cost of
production. They replaced the central c-peptide of hu-
man insulin with a trypsin cleavable mini c-peptide
(AAK). The purified desB30 insulin could be enzymati-
cally matured through trypsin treatment to remove the
central mini c-peptide. Mature insulin accumulated up-
to 0.13% of total seed protein. Biological activity of
the isolated insulin was demonstrated by an insulin tol-
erance test in mice and phosphorylation assay in a
mammalian cell culture system. Boothe et al 16 utilized
a similar strategy to produce the oleosin-insulin fusion
protein in safflower seeds for industrial exploitation of
the system. The safflower produced insulin is currently
under clinical trials with promising initial results.16
Ruhlman et al 19 produced cholera toxin B subunit-hu-
man proinsulin (CTB-Pins) fusion protein in chloro-
plasts of transgenic tobacco and lettuce with a view of
developing an oral delivery system for insulin to target
insulitis. Eight milligrams of leaf powder from trans-
genic tobacco expressing the fusion protein were fed to
non-obese diabetic mice for seven weeks. After the
study, normal blood and urine glucose level were ob-
served in CTB-Pins treated mice with reduced insulitis
and reduced damage of β-cells of pancreas. Research is
currently being conducted to optimize plant produc-
tion systems for achieving the goal of high level produc-
tion capability and much cheaper availability of insu-
lin. Hopefully, in the near future we will see plant
based insulin easily available in the market to meet the
demand of the masses.
INSULINTYPES ACCORDINGTO
MODE OF ACTION
Healthy humans produce insulin at a basal level. The
secretion of insulin increases to a peak level 1 h after
eating and dropping back to normal level after a fur-
ther 2 h. To achieve a normal 24 h insulin profile and
avoid nocturnal hypoglycaemia in diabetic patients, a
single insulin formulation with a specific onset of ac-
tion, peak effect time and duration of action cannot be
used. Normally, when insulin is injected into the body,
the insulin molecules form hexamers. For diffusion
through interstitial fluid and penetration into the capil-
lary walls to enter the bloodstream these hexamers
need to dissociate into dimers and monomers.20 There-
fore, different formulations of insulin with different on-
set of action, peak effect and duration of action have
been developed to meet specific needs of patients.
These formulations change the rate of dissociation of
hexamers into dimers and monomers and the resulting
movement of free insulin molecules in the blood
stream. These different types of insulin formulation are
described in the following sections.
Rapid acting insulin
These insulin analogs have a more rapid onset of ac-
tion (15-30 min) and shorter activity duration (4 to 5 h).
Their peak action ranges from 30-90 min post injec-
tion. By a single or two amino acid alterations in the
insulin molecule, the ability to associate into hexamers
is reduced such that they are readily absorbed, howev-
er, these modifications do not change the biological
properties of these analogs.21,22 Examples of rapid acting
insulin include Lispro and Aspart. In Insulin Lispro
(LysB28, ProB29), the positions of proline at position
B28 and lysine at position B29 in the B chain have
been reversed.21 In insulin Aspart, the proline at posi-
tion 28 has been replaced by aspartic acid.22 These rap-
id acting analogs can be used at mealtime to achieve
optimum level of insulin for utilization of glucose re-
leased after eating.
Short acting insulin
Short acting insulin analogs have an onset of action of
around 0.5-1 h, peak action of 2-4 h and activity dura-
tion of 6-8 h. Examples of these preparations include
Actrapid, Humulin, Hypurin and Neutral. These insu-
lin analogs should be injected into the body 20-30 min
before meal so as to get optimum insulin activity for
carbohydrate metabolism.
Intermediate acting insulin
Intermediate acting insulin analogs have an onset of
action around 1-2 h, peak action of 6-10 h and activ-
ity duration of 10-16 h. Examples of intermediate
acting insulin include NPH (Neutral Protamine
Hagedorn) and LENTE (from the Latin "lentus,"
meaning slow, or sluggish) insulin. The absorption
rate of NPH insulin is reduced by the addition of
protamine to the insulin preparation. In insulin
LENTE, the same is achieved by the addition of zinc
to the insulin preparation.
Long acting insulin
These insulin analogs have an onset of action around 2 h,
peak action (sometimes no peak action) of 6-20 h and
activity duration of up to 36 h. One way to prolong in-
sulin activity is designing analogs with more positively
charged amino acids so as to raise the isoelectric point
of insulin to near neutral pH.23 This helps in reducing
the solubility of insulin at neutral pH after injection in-
to the body and the absorption into the blood stream
will be delayed. Some of the long acting insulin prepa-
rations also have protamine or zinc added to them to
increase absorption time. Insulin detemir, also called
desB30 insulin, is an example of long acting insulin. In
insulin detemir, the threonine at position B30 in the B
chain is removed and a 14-C fatty acid i.e. myristic ac-
id is attached to the lysine at position B29 in the B
chain.15,16 Attachment of myristic acid helps in insulin
hexamer formation and increases the binding of insulin
to plasma albumin which delays the free insulin release
and which prolongs the activity of insulin.24
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CONCLUSION
Incidence of diabetes is increasing at an alarming rate.
Exogenous supply of insulin is needed consistently for
type 1 diabetes treatment and type 2 diabetes also
needs to be cured by the exogenous supply of insulin
in advance stages of the disease. The current sources of
insulin will not be enough in the near future to pro-
vide insulin to the vast majority of patients especially
in the poor countries. Hence, alternative production
systems like plants need to be investigated to meet the
demands of near future.
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